The pharmaceutical outsourcing giant Lonza has completed the expansion of its facilities in Visp, Valais. Thanks to this work, the company has new capacities for the production of antibody-drug conjugates (ADC).
This capacity increase underscores the strategic importance the company places on ADCs, Lonza wrote in a statement Wednesday.
The ADC market is set to experience solid growth, driven by growing demand for newer cancer therapies that are now better targeted. The company thus claims to be well positioned to take advantage of this trend.
/ATS
Related posts:
How do you use Generative Fill in Photoshop to create amazing images?
“Work is not a fairy tale”: in disguise, a CEO empties his heart on telework
ON VIDEO | A suspect steals a police car and jumps out of it while driving at full speed
Wall Street evolves divided while waiting for Fed boss Jerome Powell
3 Reasons Why Ethereum Price Could Reach $5,000: Analysis & Prediction
A partnership agreement signed with SIG and CDC Habitat
Spot Super Bowl 2023
French Electricity Bill Increases: Calls for Revaluation of Energy Check